

might thus have been regarded as a zoonosis in the very first phase but later has spread in the human population as a typical anthroponosis and caused the present pandemic. Similarly, pandemic strains of influenza developed through an antigenic shift from avian influenza A viruses. For some etiologic agents or their genotypes, both animals and humans are concurrent reservoirs (hepatitis virus E, Norwalk-like calicivirus, enteropathogenic *Escherichia coli*, *Pneumocystis*, *Cryptosporidium*, *Giardia*, and *Cyclospora*); these diseases might conditionally be called anthro-zoonoses. Other difficulties can occur with classifying diseases caused by sporulating bacteria (*Clostridium* and *Bacillus*): Their infective spores survive in the soil or in other substrata for very long periods, though they are usually produced after a vegetative growth in the abiotic environment, which can include animal carcasses. These diseases should therefore be called saprozonoses. For some other etiologic agents, both animals and abiotic environment can be the reservoir (*Listeria*, *Erysipelothrix*, *Yersinia pseudotuberculosis*, *Burkholderia pseudomallei*, and *Rhodococcus equi*), and the diseases might be, in fact, called saprozonosis (not sensu 9) in that their source can be either an animal or an abiotic substrate.

For a concise list of anthro-, zoo-, and saprozonoses, see the online appendix available from: URL: <http://www.cdc.gov/ncidod/EID/vol9no3/02-0208-app.htm>.

Zdenek Hubálek*

*Academy of Sciences, Brno, Czech Republic

References

1. Lederberg J. Infectious disease as an evolutionary paradigm. *Emerg Infect Dis* 1997;3:417–23.
2. Bell JC, Palmer SR, Payne JM. The zoonoses (infections transmitted from animals to man). London: Arnold; 1988.
3. World Health Organization. Joint WHO/FAO expert committee on zoonoses. 2nd report. WHO technical report series no. 169, Geneva; 1959. 3rd report, WHO Technical Report Series no. 378, Geneva; The Organization; 1967.
4. Pavlovsky EN. Natural nidity of transmissible diseases. Urbana (IL): University of Illinois Press; 1966.
5. Beaty BJ, Marquardt WC, editors. The biology of disease vectors. Niwot (CO): University Press of Colorado; 1996.
6. Terskikh VI. Diseases of humans and animals caused by microbes able to reproduce in an abiotic environment that represents their living habitat (in Russian). *Zhurn Mikrobiol Epidemiol Immunobiol* (Moscow) 1958;8:118–22.
7. Somov GP, Litvin VJ. Saprophytism and parasitism of pathogenic bacteria—ecological aspects (in Russian). Novosibirsk: Nauka; 1988.
8. Krauss H, Weber A, Enders B, Schiefer HG, Slenczka W, Zahner H. Zoonosen, 2. Aufl. Köln: Deutscher Ärzte-Verlag; 1997.
9. Schwabe CV. Veterinary medicine and human health. Baltimore: Williams & Wilkins; 1964.

Address for correspondence: Zdenek Hubálek, Institute of Vertebrate Biology, Academy of Sciences, Klášterní 2, CZ-69142 Valtice, Czech Republic; fax: 420-519352387; e-mail: zhubalek@brno.cas.cz

Multidrug-Resistant *Shigella dysenteriae* Type 1: Forerunners of a New Epidemic Strain in Eastern India?

To the Editor: Multidrug-resistant *Shigella dysenteriae* type 1 caused an extensive epidemic of shigellosis in eastern India in 1984 (1). These strains were, however, sensitive to nalidixic acid, and clinicians found excellent results by using it to treat bacillary dysentery cases. Subsequently, in 1988 in Tripura, an eastern Indian state, a similar outbreak of shigellosis occurred in which the isolated strains of *S. dysenteriae* type 1 were even resistant to nalidixic acid (2). Since then, few cases of shigellosis have occurred in this region, and *S. dysenteriae* type 1 strains are scarcely encountered (3). In

other regions of the world, especially in Southeast Asia, low-level resistance to fluoroquinolones in *Shigella* spp. has been observed for some time (4,5).

After a lapse of almost 14 years, clusters of patients with acute bacillary dysentery were seen at the subdivisional hospital, Diamond Harbour, in eastern India. No cases of dysentery had been reported during the comparable period in previous years. A total of 1,124 case-patients were admitted from March through June 2002. The startling feature of these infections was their unresponsiveness to even the newer fluoroquinolones such as norfloxacin and ciprofloxacin, the drugs often used to treat shigellosis. Clinicians tried various antibiotics, mostly in combinations, without benefit. Clinicians also randomly used anti-amoebic drugs without success.

An investigating team collected nine fresh fecal samples from dysentery patients admitted to this hospital; 4 (44%) yielded *S. dysenteriae* type 1 on culture. For isolation of *Shigella* spp., stool samples were inoculated into MacConkey agar and Hektoen Enteric agar (Difco, Detroit, MI), and the characteristic colonies were identified by standard biochemical methods (6). Subsequently, serogroups and serotypes were determined by visual inspection of slide agglutination tests with commercial antisera (Denka Seiken, Tokyo). Antimicrobial susceptibility testing was performed by an agar diffusion disk method, as recommended by the National Committee for Clinical Laboratory Standards (7). Results showed that the organisms were resistant to all commonly used antibiotics, including the fluoroquinolones (norfloxacin and ciprofloxacin) but were sensitive to ofloxacin. On our advice, the clinicians used ofloxacin with good results.

A similar outbreak of *S. dysenteriae* type 1 occurred in the northern part of West Bengal in eastern India among tea garden laborers from April 2002 to May 2002; 1,728 persons were affected (attack rate of 25.6%). Sixteen persons died. The isolated *S. dysenteriae* type 1 strains were found intermediately sensi-

tive to fluoroquinolones with an MIC of 2 µg/mL (K. Sarkar, S. Ghosh, S.K. Niyogi, S.K. Bhattacharya, pers. commun.).

This drug-resistant Shiga bacillus is highly likely to spread further and will certainly pose a major therapeutic challenge unless adequate preventive measures are immediately instituted to contain its spread. Appropriate awareness programs for the community and reorientation training for physicians and other health personnel would be helpful to prevent further transmission of these resistant organisms. Alternative drugs to treat drug-resistant cases and an effective vaccine are also needed.

**Dipika Sur,* Swapan K. Niyogi,*
Shravani Sur,† Kamal K. Datta,*
Yoshifumi Takeda,‡
Gopinath Balakrish Nair,§
and Sujit K. Bhattacharya***

*National Institute of Cholera and Enteric Diseases, Kolkata, India; †Burdwan Medical College, Burdwan, West Bengal; ‡Jissen Women's University, Tokyo, Japan; and §International Centre for Diarrhoeal Diseases Research, Dhaka, Bangladesh

References

1. Pal SC. Epidemic bacillary dysentery in West Bengal. *Lancet* 1984;1:1462.
2. Sen D, Dutta P, Deb BC, Pal SC. Nalidixic acid resistant *Shigella dysenteriae* type 1 in eastern India. *Lancet* 1988;2:911.
3. Niyogi SK, Mitra U, Dutta P. Changing pattern of serotypes and antimicrobial susceptibility of *Shigella* species isolated from children in Calcutta, India. *Jpn J Infect Dis* 2001;54:121-2.
4. Anh NT, Cam PD, Dalgaard A. Antimicrobial resistance of *Shigella* spp. isolated from diarrhoeal patients between 1989 and 1998 in Vietnam. *Southeast Asian J Trop Med Public Health* 2001;32:856-62.

5. Nguyen JC, Goldstein FW. Low level resistance to fluoroquinolones among *Salmonella* and *Shigella*. *Clin Microbiol Infect* 2000;6:231.
6. World Health Organization. Manual for laboratory investigations of acute enteric infections. Document WHO/CDD/83.3. Geneva: the Organization; 1983.
7. National Committee for Clinical Laboratory Standards. 1997: Performance standard for antimicrobial disk susceptibility tests: approved standards. 6th ed. NCCLS document M2-A6, Wayne (PA): The Committee; 1997.

Address for correspondence: Dipika Sur, National Institute of Cholera and Enteric Diseases, P-33 C.I.T. Road, Scheme XM, Beliaghata, Kolkata 700010, India; fax: +91 33 2350 5066; e-mail: dipikasur@hotmail.com

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

EMERGING INFECTIOUS DISEASES

Full text free online at
www.cdc.gov/eid

The print journal is available at no charge to public health professionals

YES, I would like to receive Emerging Infectious Diseases.

Please print your name and business address in the box and return by fax to 404-371-5449 or mail to

EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333

Moving? Please give us your new address (in the box) and print the number of your old mailing label here _____

EID
Online
www.cdc.gov/eid